Prognostic impact of MitraScore in elderly Asian patients with heart failure : sub-analysis of FRAGILE-HF
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology..
AIMS: MitraScore is a novel, simple, and manually calculatable risk score developed as a prognostic model for patients undergoing transcatheter edge-to-edge repair (TEER) for mitral regurgitation. As its components are considered prognostic in heart failure (HF), we aimed to investigate the usefulness of the MitraScore in HF patients.
METHODS AND RESULTS: We calculated MitraScore for 1100 elderly patients (>65 years old) hospitalized for HF in the prospective multicentre FRAGILE-HF study and compared its prognostic ability with other simple risk scores. The primary endpoint was all-cause deaths, and the secondary endpoints were the composite of all-cause deaths and HF rehospitalization and cardiovascular deaths. Overall, the mean age of 1100 patients was 80 ± 8 years, and 58% were men. The mean MitraScore was 3.2 ± 1.4, with a median of 3 (interquartile range: 2-4). A total of 326 (29.6%), 571 (51.9%), and 203 (18.5%) patients were classified into low-, moderate-, and high-risk groups based on the MitraScore, respectively. During a follow-up of 2 years, 226 all-cause deaths, 478 composite endpoints, and 183 cardiovascular deaths were observed. MitraScore successfully stratified patients for all endpoints in the Kaplan-Meier analysis (P < 0.001 for all). In multivariate analyses, MitraScore was significantly associated with all endpoints after covariate adjustments [adjusted hazard ratio (HR) (95% confidence interval): 1.22 (1.10-1.36), P < 0.001 for all-cause deaths; adjusted HR 1.17 (1.09-1.26), P < 0.001 for combined endpoints; and adjusted HR 1.24 (1.10-1.39), P < 0.001 for cardiovascular deaths]. The Hosmer-Lemeshow plot showed good calibration for all endpoints. The net reclassification improvement (NRI) analyses revealed that the MitraScore performed significantly better than other manually calculatable risk scores of HF: the GWTG-HF risk score, the BIOSTAT compact model, the AHEAD score, the AHEAD-U score, and the HANBAH score for all-cause and cardiovascular deaths, with respective continuous NRIs of 0.20, 0.22, 0.39, 0.39, and 0.29 for all-cause mortality (all P-values < 0.01) and 0.20, 0.22, 0.42, 0.40, and 0.29 for cardiovascular mortality (all P-values < 0.02).
CONCLUSIONS: MitraScore developed for patients undergoing TEER also showed strong discriminative power in HF patients. MitraScore was superior to other manually calculable simple risk scores and might be a good choice for risk assessment in clinical practice for patients receiving TEER and those with HF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
ESC heart failure - 11(2024), 2 vom: 28. März, Seite 1039-1050 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaneko, Tomohiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Heart failure |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ehf2.14658 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367338734 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367338734 | ||
| 003 | DE-627 | ||
| 005 | 20240330000813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ehf2.14658 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM367338734 | ||
| 035 | |a (NLM)38243376 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaneko, Tomohiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic impact of MitraScore in elderly Asian patients with heart failure |b sub-analysis of FRAGILE-HF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. | ||
| 520 | |a AIMS: MitraScore is a novel, simple, and manually calculatable risk score developed as a prognostic model for patients undergoing transcatheter edge-to-edge repair (TEER) for mitral regurgitation. As its components are considered prognostic in heart failure (HF), we aimed to investigate the usefulness of the MitraScore in HF patients | ||
| 520 | |a METHODS AND RESULTS: We calculated MitraScore for 1100 elderly patients (>65 years old) hospitalized for HF in the prospective multicentre FRAGILE-HF study and compared its prognostic ability with other simple risk scores. The primary endpoint was all-cause deaths, and the secondary endpoints were the composite of all-cause deaths and HF rehospitalization and cardiovascular deaths. Overall, the mean age of 1100 patients was 80 ± 8 years, and 58% were men. The mean MitraScore was 3.2 ± 1.4, with a median of 3 (interquartile range: 2-4). A total of 326 (29.6%), 571 (51.9%), and 203 (18.5%) patients were classified into low-, moderate-, and high-risk groups based on the MitraScore, respectively. During a follow-up of 2 years, 226 all-cause deaths, 478 composite endpoints, and 183 cardiovascular deaths were observed. MitraScore successfully stratified patients for all endpoints in the Kaplan-Meier analysis (P < 0.001 for all). In multivariate analyses, MitraScore was significantly associated with all endpoints after covariate adjustments [adjusted hazard ratio (HR) (95% confidence interval): 1.22 (1.10-1.36), P < 0.001 for all-cause deaths; adjusted HR 1.17 (1.09-1.26), P < 0.001 for combined endpoints; and adjusted HR 1.24 (1.10-1.39), P < 0.001 for cardiovascular deaths]. The Hosmer-Lemeshow plot showed good calibration for all endpoints. The net reclassification improvement (NRI) analyses revealed that the MitraScore performed significantly better than other manually calculatable risk scores of HF: the GWTG-HF risk score, the BIOSTAT compact model, the AHEAD score, the AHEAD-U score, and the HANBAH score for all-cause and cardiovascular deaths, with respective continuous NRIs of 0.20, 0.22, 0.39, 0.39, and 0.29 for all-cause mortality (all P-values < 0.01) and 0.20, 0.22, 0.42, 0.40, and 0.29 for cardiovascular mortality (all P-values < 0.02) | ||
| 520 | |a CONCLUSIONS: MitraScore developed for patients undergoing TEER also showed strong discriminative power in HF patients. MitraScore was superior to other manually calculable simple risk scores and might be a good choice for risk assessment in clinical practice for patients receiving TEER and those with HF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a MitraScore | |
| 650 | 4 | |a Risk score | |
| 650 | 4 | |a Transcatheter edge‐to‐edge repair | |
| 700 | 1 | |a Kagiyama, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kasai, Takatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kamiya, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Kazuya |e verfasserin |4 aut | |
| 700 | 1 | |a Ogasahara, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Maekawa, Emi |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kitai, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Jujo, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Daichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hiki, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Sunayama, Tsutomu |e verfasserin |4 aut | |
| 700 | 1 | |a Dotare, Taishi |e verfasserin |4 aut | |
| 700 | 1 | |a Nagamatsu, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Ozawa, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Izawa, Katsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Aizawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Makino, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Oka, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Momomura, Shin-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsue, Yuya |e verfasserin |4 aut | |
| 700 | 1 | |a Minamino, Tohru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESC heart failure |d 2014 |g 11(2024), 2 vom: 28. März, Seite 1039-1050 |w (DE-627)NLM261791397 |x 2055-5822 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:2 |g day:28 |g month:03 |g pages:1039-1050 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ehf2.14658 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 2 |b 28 |c 03 |h 1039-1050 | ||